UAE-based femtech pioneer Ovasave has successfully closed a significant $1.2 million pre-Seed funding round, marking a pivotal moment for women’s health technology in the region. This strategic investment will fuel the company’s ambitious expansion into Saudi Arabia and across the broader GCC, addressing a critical and underserved market for fertility and reproductive healthcare services.
Strategic Investment Propels Regional Growth
Ovasave’s pre-Seed round was co-led by US-based venture capital firm SOSV and an undisclosed UAE-based VC firm, with participation from several family offices. This diverse investor backing underscores the growing confidence in MENA’s health tech sector and the urgent demand for specialized healthcare solutions. The capital injection will primarily be allocated to scaling Ovasave’s operations, enhancing its technological platform, and establishing a robust presence in key markets, beginning with Saudi Arabia.
The investment reflects a broader trend of increasing investor interest in sector-specific solutions within the MENA startup ecosystem. As digital transformation accelerates across the region, venture capitalists are keenly looking for startups that leverage technology to solve fundamental societal challenges, particularly in healthcare. Ovasave’s focus on an often-stigmatized yet rapidly growing segment of healthcare positions it uniquely for impactful growth and investor returns.
Addressing MENA’s Fertility Healthcare Gap
Ovasave, co-founded by Dr. Lubna Hasan and Dr. Simit Kumar, aims to revolutionize the fertility journey by offering a comprehensive, end-to-end platform. Their services span egg freezing, In Vitro Fertilization (IVF), genetic testing, and holistic wellness support. This integrated approach tackles several pain points prevalent in the MENA region, including the high cost of treatments, lack of transparency, and limited access to specialized care, particularly outside major urban centers.
The demand for fertility services in the MENA region is experiencing significant growth, with projections estimating the market to reach $1.6 billion by 2030, growing at a Compound Annual Growth Rate (CAGR) of 7.9%. This surge is driven by factors such as rising infertility rates, an increasing trend of delayed marriages, and evolving societal perceptions around fertility treatments. Ovasave’s model emphasizes affordability and accessibility through transparent pricing and personalized care plans, delivered via strategic partnerships with leading clinics and laboratories.
The company’s innovative use of technology, including AI-powered assessments and personalized treatment roadmaps, is designed to streamline the patient experience. By bridging the gap between patients and high-quality care providers, Ovasave is poised to become a critical enabler of accessible fertility solutions, empowering individuals and couples across the region to make informed decisions about their reproductive health. This venture not only addresses a healthcare need but also contributes to breaking down societal barriers surrounding fertility discussions.
About Ovasave
Ovasave is a pioneering UAE-based femtech startup dedicated to making fertility and reproductive healthcare accessible, affordable, and personalized. Co-founded by Dr. Lubna Hasan and Dr. Simit Kumar, the company offers a comprehensive digital platform that guides individuals through their fertility journey, from initial assessments and consultations to facilitating advanced treatments like egg freezing and IVF. Ovasave focuses on transparent pricing, tailored treatment plans, and emotional support, working in collaboration with a network of top-tier clinics and laboratories. Its mission is to empower individuals with choices and comprehensive support throughout their reproductive health decisions.
Looking Ahead
With this fresh capital, Ovasave is set to enhance its technological infrastructure, expand its team, and solidify its presence in the strategically important Saudi Arabian market before further expanding across the GCC. The company’s immediate focus will be on building strong partnerships within the Saudi healthcare ecosystem and raising awareness about accessible fertility options. “This funding empowers us to scale our innovative platform and bring much-needed, comprehensive fertility solutions closer to women across the MENA region,” stated a company representative, highlighting Ovasave’s commitment to transforming the femtech landscape.
The success of Ovasave is a testament to the vibrancy of the UAE’s startup ecosystem and its capacity to foster innovation in critical sectors. As the MENA region continues to diversify its economy and prioritize healthcare innovation, companies like Ovasave will play a crucial role in shaping the future of specialized medical services. Their journey will be closely watched as a benchmark for femtech and health tech ventures aiming for regional dominance and impactful patient outcomes.
Source: Wamda
